Trans-omic approach to colorectal cancer: an integrative computational and clinical perspective
Colorectal Cancer (CRC) is an important cause of cancer-related mortality world-wide. The Consensus Molecular Subtypes represent the first comprehensive molecular classification with clinical implications, but many aspects are still missing. We use a transomic approach to improve the stratification, prognosis, and treatment prediction of CRC patients.
Precision medicine is a reality in some tumor types, yet this cannot be said for CRC, where predictive biomarkers are scarce and are more effective at identifying non-responders than patients who may benefit from treatment. Here, we aim to provide insights into CRC and therapy responsiveness by combining different omics approaches, such as genomics, histomics, and pharmacogenomics, and integrating these by means of an AI-driven multimodal classifier. To improve the current understanding of the molecular basis of CRC we work on characterizing the relationship between morphology and molecular cancer variants in genotype, transcriptome, proteome and single-cell image data. In particular, variations in short tandem repeats of human genomes are associated with gene expression changes in samples from CRC patients. Here, we will systematically search for tandem repeat variations in tumors, annotating and cataloguing those variants that lead to tumorigenesis of colorectal cancer.
«Computational molecular phylogenetics gives us powerful tools for modeling and understanding the process of somatic mutation in cancer.»
Dr. Maria Anisimova
- Prof. Inti Zlobec - Institute of Pathology, University of Bern
- Dr. María Rodríguez Martínez - Computational Systems Biology, IBM Research - Rüschlikon
- Prof. Berend Snijder - Institute of Molecular Systems Biology, ETH Zurich
- Prof. Andreas Fischer - Institute of Complex Systems (iCoSys), School of Engineering and Architecture Fribourg and HESO Sierre
- Prof. Viktor Koelzer - Institute of Pathology, University of Zürich
Funding: The project is funded for 4 years by the SNSF Sinergia scheme (2.9 million CHF).